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1552Objective: Most cardiac preservation solutions provide safe cold ischemic storage times for 4 to 5 hours. Our
aim was to investigate the effects of 8 hours of cold static storage (4C) using 2 normokalemic, polarizing
adenosine-lidocaine (Adenocaine; Hibernation Therapeutics Global Ltd, Kilquade, Ireland) solutions and to
compare their functional recovery with hearts preserved in gold standard histidine-tryptophan-ketoglutarate
(Custodiol-HTK; Essential Pharma, Newtown, Pa) and Celsior (Genzyme, Cambridge, Mass) solutions.
Methods: Male Sprague–Dawley rats (350–450 g) were randomly assigned to 1 of 4 groups (n ¼ 8): (1)
adenosine-lidocaine cardioplegia with low Ca2þ/high Mg2þ; (2) 23 adenosine-lidocaine cardioplegia, low
Ca2þ/high Mg2þ, melatonin, and insulin (23 adenosine, lidocaine, melatonin, and insulin); (3) histidine-
tryptophan-ketoglutarate solution; or (4) Celsior. Hearts were perfused in working mode, arrested (37C), re-
moved, stored for 8 hours at 4C, reattached in Langendorff mode and rewarmed for 5 minutes (37C), and
switched to working mode for 60 minutes. Myocardial oxygen consumption, effluent lactates, and troponin T
levels were measured.
Results:Hearts preserved for 8 hours in adenosine-lidocaine and 23 adenosine, lidocaine, melatonin, and insulin
returned 50% and 76% of aortic flow and 70% and 86% of coronary flow, respectively, at 60 minutes of reper-
fusion. In contrast, Custodiol-HTK and Celsior hearts returned 2% and 17% of aortic flow and 11% and 48% of
coronary flow, respectively, at 60 minutes of reperfusion. Hearts preserved in adenosine-lidocaine and 23 aden-
osine, lidocaine, melatonin, and insulin returned 90% and 100% of developed pressures and 101% and 104% of
heart rate, respectively. Hearts preserved in histidine-tryptophan-ketoglutarate failed to increase systolic pressure
greater than 14mmHg (11% baseline) and diastolic pressure greater than 10mmHg (17% baseline), and recov-
ered only 16% of heart rate. Hearts preserved in Celsior developed 70% of baseline systolic pressures and 86%
recovery of heart rate. At 5 minutes of rewarming after cold storage, the myocardial oxygen consumption for
hearts preserved in adenosine-lidocaine, 23 adenosine, lidocaine, melatonin, and insulin, Custodiol-HTK, and
Celsior was 23.0 5, 20 4, 15 1, and 10 2 mmol O2/min/g dry wt, respectively, with corresponding lactate
outputs of 1.8 0.8, 1.5 0.7, 2.6 0.7, and 3.2 1.4 mmol lactate/min/g dry weight. Troponin Twas not de-
tected in the coronary effluent of adenosine-lidocaine or 23 adenosine, lidocaine, melatonin, and insulin hearts,
whereas Custodiol-HTK and Celsior hearts had troponin T levels of 0.08 and 0.24 mg/mL, respectively.
Conclusions:We report a 78% return of cardiac output, 90% to 100% return of developed pressures, and 101%
to 104% return of heart rate after 8 hours of cold static storage using normokalemic, adenosine, lidocaine, mel-
atonin, and insulin preservation solution in the isolated rat heart compared with 55% cardiac output with polar-
izing adenosine-lidocaine cardioplegia alone, 4% cardiac output with Custodiol-HTK, and 25% cardiac output
in Celsior preservation solutions. (J Thorac Cardiovasc Surg 2011;142:1552-61)Froma scientific standpoint, depolarizing potassium concen-
trations of 10 mEq/L and above in surgical cardioplegia ore Heart Research Laboratory, Department of Physiology and Pharmacology,
Cook University, Townsville, Queensland, Australia.
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The Journal of Thoracic and Cardiovascular Surheart preservation solutions may not afford optimal arrest
and protection.1 In 2004, we introduced a new concept of
polarized arrest for surgical cardioplegia using a composition
of adenosine and lidocaine (Adenocaine; Hibernation
Therapeutics Global Ltd, Kilquade, Ireland) in a physiologic
Krebs–Henseleit solution.1,2We reported that Adenocaine in
a normokalemic solution arrested the heart by ‘‘clamping’’
the myocyte’s diastolic membrane potential at or
approximately80 mV with an accompanying decrease in
myocardial oxygen consumption (MVO2) of more than
95%.2 The idea was borrowed from natural hibernating ani-
mals (or summer estivators) who do not flood their cells with
high potassium and depolarize their cell membranes as theygery c December 2011
Abbreviations and Acronyms
AF ¼ aortic flow
AL ¼ adenosine-lidocaine
ALMI ¼ adenosine, lidocaine,
melatonin, and insulin
ANOVA ¼ analysis of variance
CF ¼ coronary flow
CO ¼ cardiac output
Custodiol-HTK ¼ Custodiol histidine-
tryptophan-ketoglutarate
MVO2 ¼ myocardial oxygen
consumption
RPP ¼ rate-pressure product
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The question posed was ‘‘Could the human heart in cardiac
surgery be pharmacologically manipulated to operate more
like a heart from a natural hibernator?’’ The early objective
was to inhibit the voltage-dependent Naþ fast channels re-
sponsible for the phase O upstroke (lidocaine) and simulta-
neously decrease the action potential duration (open Kþ
channels) of atria, Purkinjefibers, andventricles (adenosine),
which would theoretically arrest the heart in a more ‘‘natu-
ral’’ polarized, diastolic state compared with hyperkalemic
depolarized arrest.
The adenosine-lidocaine (AL) polarizing arrest and pro-
tection concept has subsequently received proof-of-concept
in the canine model of cardiopulmonary bypass4 and is used
clinically in a number of US centers as Adenocaine all-
blood microplegia.5 In 2008, Jin and colleagues6 carried
out a 134-patient pediatric safety trial and showed that
AL crystalloid ‘‘one shot’’ with moderate hyperkalemia
(10 mmol/L) was more protective than AL with 20 mmol/L
Kþ or 20 mmol/L Kþ alone. In 2010, we confirmed the im-
portance of keeping potassium within its normokalemic
limits for optimal AL polarized protection at 32C to
33C in isolated rat hearts and showed that higher (depola-
rizing) or lower (hyperpolarizing) extracellular potassium
arrest resulted in significantly higher coronary vascular re-
sistances, slower times to first beat (stunning), and lower
cardiac outputs (COs) with lower contractility.1,7
AL cardioplegia also appears versatile as a preservation
solution at both cold static storage (4C) and warmer inter-
mittent perfusion (28C–30C) compared with Celsior
(Genzyme, Cambridge, Mass).8 In 2011, we reported that
reperfusing the isolated rat heart for 5 minutes with
warm, oxygenated polarizing AL arrest after 6 hours of
cold storage in AL cardioplegia or Celsior led to signifi-
cantly higher recoveries and may offer a new paradigm of
polarizing protection for rewarming and implantation.9
The aim of the present study is to investigate the effectsThe Journal of Thoracic and Carof 8 hours of cold static storage (4C) using 2 modified
AL (Adenocaine) preservation solutions and compare
them with Custodiol histidine-tryptophan-ketoglutarate
(Custodiol-HTK; Essential Pharma, Newtown, Pa) and
Celsior solutions.
MATERIALS AND METHODS
Animals
Male Sprague–Dawley rats (350–450 g, n ¼ 40) were obtained from
James Cook University’s breeding colony. Animals were fed ad libitum
and housed in 10/14 hour light/dark cycle. On the day of experiment, rats
were anesthetized with an intraperitoneal injection of thiopentone sodium
(Thiobarb; 60 mg/kg body wt [Lyppard, Queensland, Australia]), and the
hearts were rapidly excised as described by Dobson and Jones.2 Rats
were handled in compliancewith JamesCookUniversity Guidelines (ethics
approval numbers A1084 and A1515) and the ‘‘Guide for Care and use of
Laboratory Animals’’ from the National Institutes of Health (Publication
No. 85-23, revised 1985, and PHS Publication 1996). Adenosine (A9251
> 99% purity), histidine, histidine-HCl, tryptophan, alpha-ketoglutarate,
mannitol, and melatonin (N-acetyl-5-methoxytryptamine) were obtained
from Sigma Chemical Company (Castle Hill, NSW, Australia). Lidocaine
hydrochloride (2% solution, ilium) and insulin (40 IU/mL) were obtained
from Lyppard (Queensland, Australia). Celsior was purchased as a Food
and Drug Administration-approved product from Clifford Hallam Health-
care (Agent for Genzyme, North Ryde, NSW, Australia).
Arrest Solutions for Normothermic Induction and
Cold Static Storage
Adenosine-lidocaine solution with low Ca2þ/high Mg2þ.
The AL cardioplegia contained 200 mmol/L adenosine plus 500 mmol/L li-
docaine in 10 mmol/L glucose containing modified Krebs–Henseleit buffer
(pH 7.7 at 37C) with low Ca2þ/high Mg2 (0.22 mmol/L CaCl2 and 2.6
mmol/L MgCl2). The solution was filtered using 0.2-mm filters and main-
tained at 37C. These AL concentrations have been used in previous cardi-
oplegia and preservation studies.8,9 The arrest solution was not actively
bubbled with 95% O2/5% CO2, thus the higher pH. The average PO2 of
the AL solution at the beginning of storage was 140 mm Hg and the
PCO2 was 5 to 10 mm Hg.
23 adenosine-lidocaine solution with low Ca2þ/high
Mg2þ, melatonin, and insulin. The composition was the same
as the AL solution (above) with the following additions: twice the con-
centration of A and L (400 mmol/L and 1000 mmol/L), 100 mmol/L mel-
atonin, and 0.01 IU/mL insulin. The reason for doubling AL was from
previous 6-hour cold static storage studies that showed a moderate but
significant 1.3-fold increase in left ventricular function (aortic flow
[AF]) and improved electrical stability (n ¼ 6; D.M.R. and G.P.D. unpub-
lished data, 2010). Higher AL concentrations may also improve protec-
tion because lidocaine is known to have a reduced ability to block
sodium fast channels at lower temperatures10 (and perhaps the same ex-
ists for adenosine and adenosine receptors). The naturally occurring pi-
neal gland hormone melatonin was chosen because it is a free radical
scavenger (5 times more effective in neutralizing OH radicals than glu-
tathione) and is a powerful antioxidant with cardioprotective properties.11
Insulin was chosen because of its antioxidant and cardioprotective prop-
erties (see ‘‘Discussion’’).12 Preliminary experiments showed that melato-
nin and insulin added to AL arrest solution, singly or in combination,
improved functional recoveries after 6 hours of cold static storage. The
concentrations of each drug were chosen from their cardioprotective
properties in the isolated perfused heart.11,12
Celsior solution. The Celsior solution contained 100 mmol/L NaOH,
15 mmol/L KCl, 13 mmol/L MgCl2, 0.25 mmol/L CaCl2, 20 mmol/L
glutamic acid, 80 mmol/L lactobionic acid, 30 mmol/L histidine, and 3diovascular Surgery c Volume 142, Number 6 1553
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nomodification. The solutionwasfilteredwith a 0.2-mmol/Lfilter, was not ac-
tively bubbledwith 95%O2/5%CO2, and had an average PO2 of 149mm/Hg.
Custodiol histidine-tryptophan-ketoglutarate solution.
The Custodiol-HTK solution contained 15 mmol/L NaCl, 9 mmol/L
KCl, 4.0 mmol/L MgCl2, 0.015 mmol/L CaCl2, 1.0 mmol/L alpha-
ketoglutarate, 180 mmol/L histidine, 18 mmol/L histidine-HCl, 30
mmol/L mannitol, and 2 mmol/L tryptophan.13,14
Arrest Solutions for 5 Minutes of Warm Reperfusion
After Cold Static Storage
The AL and ALMI, Celsior, and Custodiol-HTK arrest solutions were
the same as described above except they were actively bubbled with
95% O2/5% CO2 to achieve a PO2 greater than 600 mm Hg, and the solu-
tions were not recirculated.
Composition of Modified Krebs–Henseleit for
Reperfusion in Working Mode
The modified Krebs–Henseleit buffer contained 10 mmol/L glucose,
117 mmol/L NaCl, 5.9 mmol/L KCl, 25 mmol/L NaHCO3, 1.2 mmol/L
NaH2PO4, 1.12 mmol/L CaCl2 (free Ca
2þ ¼ 1.07 mmol/L), and 0.512
mmol/L MgCl2 (free Mg
2þ¼ 0.5 mmol/L), pH 7.4 at 37C. The perfusion
buffer was filtered using a 1-mmol/L membrane and then bubbled vigor-
ously with 95% O2/5% CO2 to achieve a PO2 greater than 600 mm Hg.
The perfusion buffer was not recirculated.
Experimental Groups
Rats were randomly assigned to 1 of 4 groups (n ¼ 8 each group): (1)
AL cardioplegia; (2) 2 3 AL cardioplegia with low Ca2þ/high Mg2þ, mel-
atonin, and insulin; (3) Celsior; or (4) Custodiol-HTK solution.
Langendorff and working rat heart preparation. Hearts
were rapidly removed from anesthetized rats and placed in ice-cold, hepa-
rinized, modified Krebs–Henseleit buffer (Figure 1). The details of heart
preparation, surgical attachment, and perfusion have been described byFIGURE 1. Experimental protocol. Isolated rat hearts were placed in cold stat
Mg2þ(0.22 mmol/L/2.6 mmol/L); (2) AL doubled in concentration with melaton
and (4) Celsior depolarizing preservation solutions. Each group was rewarmed
solution (see ‘‘Materials andMethods’’ for details).AL,Adenosine-lidocaine;AL
tryptophan-ketoglutarate.
1554 The Journal of Thoracic and Cardiovascular SurRudd and Dobson.8,9 Briefly, hearts were attached to a Langendorff
apparatus and perfused at a pressure head of 90 cm H2O (68 mm Hg).
The pulmonary artery was not cannulated before arrest, and the heart
was detached for 8 hours of cold static storage to prevent vessel wall
damage. The heart was cannulated after cold storage for collection of
coronary venous effluent and O2 consumption measurements. For
working mode operation, a small incision was made in the left atrial
appendage and a cannula was inserted and sutured, which was switched
from the aorta to the left atrial cannula at a hydrostatic pressure of 10 cm
H2O (preload) and an afterload pressure of 100 cm H2O (76 mm Hg).
Heart rate, aortic pressure, coronary flow, and AF were measured before
and after 8 hours of cold static storage (Figure 1). CO was the sum of aortic
and coronary flows. During the 15-minute equilibration period, the initial
criteria for exclusion of working hearts were a heart rate less than 200
beats/min, systolic pressure less than 100 mm Hg, and coronary flow less
than 10 mL/min.
Cold Static Storage (4C) and Early Reperfusion
The method of cold static storage for rat hearts has been described by
Rudd and Dobson.8,9 Briefly, hearts were arrested at a constant pressure
head of 90 cm H2O (68 mm Hg) using AL cardioplegia or Celsior
solution for 5 minutes (50–100 mL) at 37C for their respective groups.
Hearts were gently removed from the apparatus and placed in a 50-mL
tube containing their respective air-equilibrated preservation solutions,
and the sealed tube was immersed in the water bath at 4C for 8 hours
(Figure 1). After 8 hours of storage, the hearts were immediately reattached
to the perfusion apparatus, and fresh, warm oxygenated arrest solutions
(AL, 23 ALMI, Custodiol-HTK, or Celsior) were used to reperfuse the
heart in nonworking Langendorff mode at a pressure head of 90 cm H2O
(68 mm Hg) for 5 minutes (Figure 1). The heart’s surface temperature
was 28C to 32C.9 Temperature was measured using a Cole-Palmer
thermistor-thermometer (8402-20; John Morris Scientific, Bowen Hills,
Queensland, Australia), which was tucked under the left auricle. Hearts
were then switched to working mode and reperfused for 60 minutes at
37C using oxygenated glucose containing Krebs–Henseleit pH 7.4. Hearts
were allowed to spontaneously return to function during reperfusion, andic storage for 8 hours in (1) AL polarizing cardioplegia with low Ca2þ/high
in (100 mmol/L) and insulin (0.01 IU/mL) (23ALMI); (3) Custodiol-HTK;
in Langendorff mode for 5 minutes with their respective oxygenated arrest
MI, adenosine, lidocaine, melatonin, and insulin;HTK,Custodiol histidine-
gery c December 2011
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(aortic and coronary flow, heart rate, and systolic and diastolic pressures)
were measured at 5, 10, 15, 30, 45, and 60 minutes during the 60-minute
reperfusion. These data were compared with the baseline (prearrest) data
for each group. Myocardial oxygen consumption (mmole O2/min/g dry
wt heart) was calculated using equations andmethods described by Dobson
and Jones2 and Rudd and Dobson.8,9 Coronary venous effluent was
measured in milliliters/minute, and heart weight was expressed as grams
of dry weight. Total tissue water (%) was determined by the difference
in wet weight and dry weight divided by wet weight and multiplied by 100.
Lactate Output and Troponin T Release at 5 Minutes
Warm Reperfusion
Coronary effluent (1.0–1.5 mL) was collected in small 1.5-m Eppendorf
tubes during the last minute of the rewarming period and stored at20C
until analysis (2 weeks). Perfusate lactates were analyzed on Cobas
Integra 800 using a colorimetric kit purchased from Roche Diagnostics,
Brisbane, Queensland, Australia. Output results were in millimoles/liter
and converted to micromoles/minute/gram dry weight using coronary
flow (CF) and heart weight as in equation (1):
Lactate ðmmol=min=g dry wtÞ ¼ Lactate ðmmol=mLÞ3CFðmL=minÞ
3 1=heart weight ðg dry wtÞ1 (1)
Troponin Twas measured on fresh effluent using the enzyme immuno-
assay method of the Roche Cardiac T Quantitative test on the Roche
Cardiac Reader System (Roche Diagnostics). The method has a lower limit
of detection of approximately 0.03 mg/L. Broad clinical prognostic values
for troponin T reference range are as follows: no myocardial damage,TABLE 1. Functional parameters of isolated working rat hearts after
rewarming in polarizing adenosine-lidocaine and 23 adenosine, lidocaine,
Celsior solutions
Time
Cold arrest
þrewarm
treatment n
Aortic flow
(mL/min)
Coronary flow
(mL/min)
Cardiac o
(mL/m
Value % PA Value % PA Value
15 min
prearrest
AL 8 60  2 20  1 80  2
23 ALMI 8 62  1 22  1 85  2
HTK 8 54  2 19  1 73  2
Celsior 8 63  4 21  2 85  5
5-min
recovery
AL 8 0  0 0 1  1 1 1  1
23 ALMI 8 3  3 1 2  2 9 5  5
HTK 8 0  0 0 1  1 5 1  1
Celsior 8 0  0 0 3  2 14 3  2
10-min
recovery
AL 8 11  6 18 11  3 55 22  9
23 ALMI 8 14  7 22 8  4 36 22  11
HTK 8 0  0 0 2  1 11 2  1
Celsior 8 1  1 2 8  2 38 9  3
30-min
recovery
AL 8 28  5y 47 15  2y 75 43  1
23 ALMI 8 44  2* 71 18  1z,x 82 62  3z,x
HTK 8 0  0 0 2  1 11 2  1
Celsior 8 8  4 13 10  2k 48 18  6
60-min
recovery
AL 8 30  5y 50 14  2y 70 44  6y
23 ALMI 8 47  3* 76 19  1z,x 86 66  3z,x
HTK 8 1  1 2 2  1 11 3  2
Celsior 8 11  5 17 10  2k 48 21  7
See ‘‘Materials and Methods’’ for details. No significant differences between prearrest gr
HTK, Custodiol histidine-tryptophan-ketoglutarate. *ALMI significantly different from a
or both, P<.05. zALMI significantly different from Celsior only, P<.05. xALMI signifi
from Custodiol-HTK, P<.05.
The Journal of Thoracic and Car0.0–0.05 mg/L; myocardial damage possible, 0.05–0.1 mg/L; myocardial
damage detected, greater than 0.1 mg/L.15
Statistical Analysis
All results are expressed as mean  standard error of the mean. One-
way analysis of variance (ANOVA) was used to compare rat weights, arrest
times, and time to first beat and AF. Two-way ANOVAwith repeated mea-
sures was used to compare recovery variables (eg, AF, systolic and diastolic
pressures, heart rate, CO) over multiple time points for the different treat-
ment groups. One-way ANOVAwas used to compare recovery of variables
at specific times points (5, 10, 30, 45, and 60minutes) during reperfusion in
working mode. Significance was then assessed using Bonferroni and
Dunnet 2-way post hoc tests.RESULTS
Heart functional properties before and after cold static
storage in the 4 different preservation solutions are shown
in Table 1 and Figures 2 and 3. During prearrest, there
were no significant differences among the groups in AF,
CF, CO, heart rate, developed pressures, or rate-pressure
product (RPP) (Table 1).Recovery of Aortic Flow, Coronary Flow, and
Cardiac Output
Baseline values of AF ranged from 54 to 63 mL/min1.
Five minutes after switching to working mode, the8-hour cold static ischemic storage (4C) and 5-minute oxygenated
melatonin, and insulin solutions or depolarizing Custodiol-HTK and
utput
in)
Heart rate
(beats/min)
Systolic
pressure
(mm Hg)
Diastolic
pressure
(mm Hg)
Rate-pressure
product
(beats/mm Hg/min)% PA Value % PA
280  7 124  2 60  0 34,561  584
303  7 128  1 60  0 38,836  957
275  8 125  1 60  0 34,404  943
286  12 126  2 60  0 36,041  1268
1 4  4 1 3  3 1  1 80  80
6 25  25 8 16  16 8  8 3250  3250
1 22  7 8 14  5 9  3 446  201
4 48  13 17 31  9 19  3 1998  935
28 139  44 50 71  17 40  10 14,673  5320
26 118  50 39 51  20 25  10 13,078  6316
3 39  21 14 15  9 10  5 1795  1377
11 176  39 62 66  10 48  8 13,944  3680
54 293  22 105 110  3 63  2 32,155  2515
73 294  16x 97 121  3z,x 60  0x 35,294  1496z,x
3 41  27 15 1 3  11 10  9 2411  2221
21 213  32k 75k 88  8k 59  5k 19,998  3834k
55 283  19 101 111  3 63  2 31,518  2346
78 314  12x 104 117  3x 60  0x 36,800  1021z,x
4 44  30 16 14  12 10  9 3396  2781
25 247  28k 86k 89  6k 62  4k 21,473  3642k
oups. AL, Adenosine-lidocaine; ALMI, adenosine, lidocaine, melatonin, and insulin;
ll other groups, P<.05. yAL significantly different from Custodiol-HTK or Celsior
cantly different from Custodiol-HTK only, P<.05. kCelsior significantly different
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FIGURE 2. A, Percentage recovery of AF (%) during 60-minute reperfu-
sion inworkingmode immediately after 5minutes of oxygenated reperfusion
inLangendorffmode. The 4 groupswere (1)AL lowCa2þ/highMg2þ(-), (2)
23 ALMI (,), (3) Custodiol-HTK (C), and (4) Celsior (B). Significance
(P<.05) was as follows: *23ALMI different from all groups. yAL different
from Celsior and Custodiol-HTK. B, Percentage recovery of coronary flow
(%) during 60-minute reperfusion (see A). xALMI significantly different
from Celsior. #ALMI significantly different from Custodiol-HTK only. yAL
significantly different from Custodiol-HTK or Celsior. zCelsior significantly
different fromCustodiol-HTK.C, Percentage recovery of CO (%) during 60-
minute reperfusion (see A). xALMI significantly different from Celsior.
#ALMI significantly different from Custodiol-HTK only. yAL significantly
different from Custodiol-HTK or Celsior. CO, Cardiac output; CF, coronary
flow; AF, aortic flow; ALMI, adenosine, lidocaine, melatonin, and insulin;
AL, adenosine-lidocaine;HTK,Custodiol histidine-tryptophan-ketoglutarate.
FIGURE 3. A, Recovery of systolic pressure (mm Hg) during 60-minute
reperfusion. xALMI significantly different from Celsior. #ALMI signifi-
cantly different from Custodiol-HTK. zCelsior significantly different
from Custodiol-HTK. B, Recovery of diastolic pressure (mm Hg) during
60-minute reperfusion. #Celsior significantly different from Custodiol-
HTK. zCelsior significantly different from Custodiol-HTK. C, Percentage
recovery of heart rate (%) during 60-minute reperfusion in working
mode immediately after 5 minutes of oxygenated reperfusion in Langen-
dorff mode. The 4 groups were (1) AL low Ca2þ/high Mg2þ (-), (2) 23
ALMI (,), (3) Custodiol-HTK (C), and (4) Celsior (B). Significance
(P<.05) was as follows: #ALMI significantly different from Custodiol-
HTK. zCelsior significantly different from Custodiol-HTK. ALMI, Adeno-
sine, lidocaine, melatonin, and insulin; AL, adenosine-lidocaine; HTK,
Custodiol histidine-tryptophan-ketoglutarate; HR, heart rate.
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(2 mL/min) (Table 1, Figure 2, A). At 10 minutes, AL and
ALMI hearts had spontaneously generated approximately1556 The Journal of Thoracic and Cardiovascular Sur20% of their respective baseline AF, whereas Custodiol-
HTK hearts had zero flow (0%) and Celsior hearts had 1
mL/min (2% of prearrest). At 30 minutes, AL and
ALMI hearts generated 47% and 71% of their prearrest
AF and increased to 50% and 76% at 60 minutesgery c December 2011
Rudd and Dobson Evolving Technology/Basic Science
E
T
/B
Sreperfusion, respectively. In contrast, hearts preserved in
Custodiol-HTK generated 0% and 2% AF after 30 and
60 minutes, respectively, and Celsior hearts generated
13% and 17% prearrest AF after 30 and 60minutes, respec-
tively (Table 1, Figure 2, A).
The spontaneous return of CF at 5 minutes for AL, 23
ALMI hearts, Custodiol-HTK, and Celsior was 1%, 9%,
5%, and 14% of baseline values, respectively, and at 10
minutes CF increased to 55%, 36%, 11%, and 38%, re-
spectively (Table 1, Figure 2, B). At 30 minutes reperfusion,
the CF increased to 75% and 48% for the AL and Celsior
hearts, respectively, whereas the 23ALMI hearts increased
2.3-fold (82% prearrest). At 60 minutes, the return of CF
for AL, 23 ALMI, and Celsior hearts was 70%, 86%,
and 48%, respectively. Custodiol-HTK hearts did not in-
crease CF from 10 to 60 minutes and remained at 11% of
prearrest value (2 mL/min1) (Table 1, Figure 2, B).
Recovery of CO at 5 minutes for all groups in working
mode ranged from 1% to 6% (Table 1, Figure 2, C). At
10 minutes, the CO for AL, 23 ALMI hearts, Custodiol-
HTK, and Celsior was 28%, 26%, 3%, and 11%, respec-
tively. At 30 minutes, the AL and 23 ALMI hearts doubled
and tripled their outputs, respectively, the Celsior hearts
doubled their output, and the Custodiol-HTK hearts failed
to increase CO above 3% of prearrest value (Table 1,
Figure 2, C). At 60 minutes, the AL hearts stabilized CO
at 55% prearrest output, 23 ALMI hearts increased to
78%, and Celsior increased to 25% prearrest output. Cus-
todiol-HTK failed to increase CO over the 60-minute period
(Table 1, Figure 2, C). Stroke volume was calculated by di-
viding CO by heart rate and ranged from 0.27 to 0.30 mL
beat1 for the 4 groups at baseline (Table 1). At 60 minutes
reperfusion, the AL and 23 ALMI hearts had recovered
55% and 75%, respectively. In direct contrast, the Custo-
diol-HTK and Celsior hearts recovered 5% and 23% of
baseline, respectively.
Recovery of Systolic and Diastolic Developed
Pressures
The systolic and diastolic pressures are shown in Table 1
and Figure 3, A and B. Baseline values ranged from 124/60
to 128/60 mm Hg and were not significantly different. At 5
minutes, the AL and 23 ALMI hearts generated 2% and
13% of baseline pressures, respectively, which rapidly in-
creased to 57% to 67% systolic and 40% to 42% diastolic
at 10 minutes, respectively (Table 1, Figure 3, A, B). At 30
and 60 minutes of reperfusion, the AL and 23ALMI hearts
had recovered 89% to 94% of systolic pressures and 105%
to 100% of diastolic pressures, respectively. Celsior hearts
showed a faster recovery at 5 minutes (25%–32% baseline)
and at 10 minutes had recovered 52% systolic and 80%
diastolic pressures. At 30 and 60 minutes, Celsior hearts
increased systolic pressure to 70% baseline, but this pres-
sure was not high enough to generate sufficient AF, andThe Journal of Thoracic and Carthe diastolic pressure was 98% to 100%. Custodiol-HTK
failed to increase systolic pressure greater than 14 mm Hg
(11% baseline), and diastolic pressure was not greater
than 10 mmHg (17% baseline) over the 60-minute reperfu-
sion period.
Recovery of Heart Rate and Rate-Pressure Product
Spontaneous return of heart rate is shown in Table 1 and
Figure 3, C. Baseline rates ranged from 275 to 303 beats/
min1. At 5 minutes, the AL, 23 ALMI, and Custodiol-
HTK hearts had a rate of 4 to 25 beats/min1; however,
the Celsior hearts had a rate of 48 beats/min1. At 10 min-
utes, the AL and 23 ALMI hearts increased their rates to
50% and 39% baseline, respectively, and Celsior hearts
were beating at 62% baseline. The Custodiol-HTK hearts
increased their heart rate from 22 to 39 beats/min1 to 44
beats/min1 (14%–16% baseline) at 10 minutes and did
not change during the 60-minute reperfusion. At 30 min-
utes, AL and 23 ALMI hearts returned 105% and 97%
of their baseline heart rates, respectively, and Celsior hearts
had 75% of the baseline rate. At 60 minutes, full recovery
of heart rate was found in the AL and 23 ALMI hearts, and
86% recovery was found in the Celsior hearts.
Baseline RPP ranged from 34,404 to 38,836 beats/mm
Hg/min1 for the 4 preservation groups (Table 1). At 5 min-
utes, return of RPP was 0.2% to 8% baseline in all groups.
At 10 minutes, the AL and 23ALMI hearts generated 42%
and 34% of baseline RPP, respectively, and the Celsior
hearts generated 39% (Table 1). The Custodiol-HTK hearts
generated 5% to 10% baseline RPP during the entire 60-
minute reperfusion period. At 30 minutes, the AL and 23
ALMI hearts nearly had full recovery of RPP (91%–93%
return) and 23 ALMI hearts had 95% at 60 minutes. The
Celsior hearts returned 55% and 59% of their RPP at 30
and 60 minutes, respectively.
Maintenance Myocardial Oxygen Consumption in
the Last Minute of the 5-Minute Rewarming Phase
Before Switching to Working Mode
At the end of the rewarming phase, theMVO2 for AL, 23
ALMI, Custodiol-HTK, and Celsior hearts in Langendorff
mode perfused with their oxygenated arrest solutions was
23.0  5, 20  4, 15  1, and 10  2 mmol O2/min/g dry
wt, respectively (Figure 4, A). AL and 23 ALMI hearts
were significantly higher than Celsior. The coronary efflu-
ent flows in the final minute were 13.7  0.9 and 14.2 
2.3 mL for AL and 23 ALMI hearts, respectively, and
11.1  0.9 and 10.8  1.4 mL for Custodiol-HTK and
Celsior hearts, respectively.
Lactate and Troponin T Output in the Last Minute of
5-Minute Rewarming
The lactate outputs for AL, 23 ALMI, Custodiol-HTK,
and Celsior hearts perfused with their oxygenated arrestdiovascular Surgery c Volume 142, Number 6 1557
FIGURE 4. A, MVO2 for the 5 different groups during 5-minute rewarm-
ing period in Langendorff mode and at 10 and 60 minutes reperfusion in
working mode. Celsior was significantly different from AL and ALMI
(P< .05). B, Lactate output (mmol/min/g dry wt heart) measured in the
last minute of the 5-minute rewarming period. Differences were not signif-
icant (P<.05). C, Troponin T measured in the last minute of the 5-minute
rewarming period. Celsior was significantly different from AL and ALMI
(P < .05). MVO2, Myocardial oxygen consumption; AL, adenosine-
lidocaine; ALMI, adenosine, lidocaine, melatonin, and insulin; HTK, Cus-
todiol histidine-tryptophan-ketoglutarate.
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mmol lactate/min/g dry wt, respectively (Figure 4, B). No
troponin T was detected in the coronary effluent of AL or1558 The Journal of Thoracic and Cardiovascular Sur23 ALMI hearts after rewarming (Figure 4, C). In contrast,
the troponin T levels for Custodiol-HTK and Celsior hearts
were 0.08 and 0.24 mg/mL effluent, respectively.
DISCUSSION
Over the past 3 decades, the design of organ preservation
solutions has been based on 3 fundamental principles: (1)
hyperkalemic arrest, (2) a suitable cold, milieu to maintain
cell viability during global ischemia, and (3) protection
from reperfusion injury.16 In 2009, we introduced a new
cold and warm normokalemic, polarizing concept to organ
preservation,1,8 and in 2011 we reported that AL
cardioplegia with 1 mmol/L Ca2þ/0.5 mmol/L Mg2þ
returned approximately 68% CO, 101% heart rate, 90%
to 105% developed pressures, and no detectable troponin
T (<0.03 mg/mL) after 6 hours of cold static storage. The
present study showed that further protection is afforded
using higher AL levels in the presence of melatonin (100
mmol/L) and insulin (0.01 IU/mL) added to the AL
preservation solution (23 ALMI); the return of CO
increased to 78% with higher functional recoveries. In
contrast and under identical conditions, Custodiol-HTK
hearts failed to function with 4% CO, 16% heart rate,
11% to 17% developed pressures, and troponin T of 0.13
mg/mL. Celsior hearts, despite an 86% return of heart
rate, also failed to return sufficient left ventricular pump
function with 25% CO and troponin T of 0.24 mg/mL
after rewarming for 8 hours and 5 minutes.
Rewarming (5 Minutes) After Cold Static Storage:
Higher Aerobic Maintenance Metabolism and Lower
Lactate Efflux in Polarized Adenosine-Lidocaine
Hearts
An interesting outcome from the present study was that
the higher functional recoveries in AL hearts were associ-
ated with higher (1.5–2-fold) rates of MVO2 in oxygenated,
normokalemic, polarized arrested hearts (AL, 23 ALMI)
before switching to working mode compared with hyperka-
lemic Custodiol-HTK and Celsior arrested hearts (Figure 3,
A). Previously, we also reported a higher aerobic mainte-
nance metabolism for AL hearts during 5 minutes of re-
warming compared with Celsior hearts after 6 hours of
cold static storage (arrested in normal AL with 1.0 mmol/L
Ca2þ/0.5 mmol/L Mg2þ).9 The higher MVO2 values in the
present study were associated with equivalent decreases in
effluent lactate (Figure 3, B), indicating an increased reli-
ance on mitochondrial oxidative phosphorylation to replen-
ish ATP compared with hyperkalemic Custodiol-HTK and
Celsior groups. These differences in MVO2 were not due
to differences in coronary effluent outflows, which ranged
from 11 to 14 mL/min. The higher troponin T levels in
the hyperkalemic Custodiol-HTK and Celsior groups indi-
cate some myocardial cell damage during 5 minutes of re-
warming and reperfusion. Troponin T was not detected ingery c December 2011
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higher MVO2 in AL-arrested hearts may provide a new po-
larizing protection paradigm for rewarming and implanting
donor hearts after cold static storage.9
Higher Functional Recoveries in Adenosine-
Lidocaine Hearts After 8 Hours of Cold Static
Storage
Adenosine-lidocaine preservation solutions. A standout
result of the present study was the spontaneous return of
55% to 78% CO after 8 hours of cold ischemic storage
with approximately 100% heart rate and 90% to 105% de-
veloped pressures for AL and 23 ALMI hearts. AL preser-
vation encompassed approximately 10 hours of protection
from harvest, arrest induction, cold static storage (4C), 5
minutes of rewarming, to 60minutes of reperfusion in work-
ing mode (38C). We previously reported a return of 66%
CO in rat hearts stored in AL cardioplegia (1.0 mmol/L
Ca2þand 0.5mmol/LMg2þ) after 5minutes of rewarming af-
ter 6 hours of cold static storage.9 Improved recovery in the
23ALMI hearts may be due to (1) the higher AL concentra-
tion exerting a stabilizing effect onmembrane polarity,10 and
thereby reducing damage from Naþand Ca2þ loading during
cold storage or rewarming; (2) insulin’s effect to possibly fa-
cilitatemyocardial glucose uptake,17 stimulation of nitric ox-
ide production via ischemia-induced myocyte protein kinase
C-dependent phosphatidylinositol 3’-kinase-Akt-dependent
signaling, and inhibition of superoxide anion (O2
)12,18;
and (3) melatonin’s cardioprotective properties. Melatonin
is a powerful antioxidant and scavenges superoxide radical
(O2
), hydroxyl radical (OH), and the lipid peroxyl radical.
Melatonin prevents the mitochondrial permeability transition
pore from opening and collapsing the membrane potential;
helps to maintain cardiolipin levels, which constitute
approximately 20% of the total lipid composition of the
inner mitochondrial membrane; and has a stabilizing effect
on components of the electron transport chain, including
preventing the loss of cytochrome c.11 The present study
did not investigate the relative contributions of 23AL, mel-
atonin, or insulin on improved pump function, and further
studies are required to tease apart theirmechanisms of action
in AL preservation and recovery.
In both AL preservation groups, the higher return of left
ventricular pump function compared with the Custodiol-
HTK and Celsior hearts may also have been associated
with improved maintenance of cell membrane polarity
during all phases of the preservation protocol.1,9 The basic
electrophysiology behind polarized versus depolarized
diastolic arrest is that at ‘‘resting’’ diastolic membrane
potentials there are fewer ‘‘open’’ membrane channels,
pores, and exchangers compared with depolarized states
that can lead to Naþ and Ca2þ loading, mitochondrial
dysfunction, cell injury, and possibly death.2,7,19 The
diastolic membrane potential of AL hearts is approximatelyThe Journal of Thoracic and Car80 mV.2,7 By using the Nernstian relation between
membrane potential (Em) and extracellular potassium,
where Em (mV)¼ 26.23 ln [Kþ(mmol/L)] – 123.44,7 we pre-
dict a membrane potential for Custodiol-HTK hearts of63
mV for an extracellular potassium level of 10 mmol/L Kþ.
Our Nernstian estimate agrees with the direct microelectrode
membrane measurement of60 3.6 mV reported by Krohn
and colleagues20 on sheep cardiac Purkinje fibers bathed in
Custodiol-HTK solution. We predict the voltage of the Cel-
sior hearts to be approximately50 mV (15 mmol/L Kþ).
Celsior Versus Custodiol Histidine-Tryptophan-
Ketoglutarate Preservation Solution
Ourfinding thatCelsior hearts performedbetter thanCusto-
diol-HTK hearts has been reported in a number of experimen-
tal and clinical investigations for solid organ transplantation in
heart,21-25 lung,26 and liver.27 Our results are consistent with
the rat heart study of Gao and colleagues,28 who reported
CO recoveries in Celsior stored hearts of 20% at 30 minutes
after 6 hours and less than 5% at 30 minutes after 10 hours
of cold static storage (2C–3C). In our study, only 10% of
left ventricular function (AF) and 25% CO were spontane-
ously returned after 8 hours of cold storage (Figure 2, A–C).
Celsior has also been reported to be clinically superior to
University of Wisconsin (Viaspan; Bristol-Myers Squibb
Pharmaceuticals Ltd, Leopardstown, Dublin, Ireland).22,25,29
Superior preservation in Celsior is believed to be due to the
lower potassium levels (15 mmol/L), low Ca2þ/high Mg2þ,
impermeant lactobionate, and potent antioxidant properties
of reduced glutathione.21,23,30-33 Celsior seems to have been
originally designed as a single-solution platform for use dur-
ingmost of the successive steps of the preservation procedure.
However, it was not designed as a normokalemic, normother-
mic reperfusion solution where the heart may be challenged
during cold-to-rewarm transitions, as we recently showed in
the rat heart after 6 hours of cold static storage.9
We were also surprised with the low ventricular outputs
from Custodiol-HTK hearts with less than a few percent re-
covery (Figure 2, A), because they, like Celsior hearts, ap-
peared healthy and soft to touch with no visual signs of
ischemia after 8 hours of cold static storage. As with Celsior
hearts, the Custodiol-HTK hearts could not generate suffi-
cient left ventricular output against a fixed pressure head,
that is, they could not perform adequate physical work
(force 3 distance) against the 76 mm Hg afterload. In
1993, Reichenspurner and colleagues34 evaluated Custo-
diol-HTK for myocardial preservation in cooperation with
Eurotransplant and 5 heart transplant centers, and it was
concluded that Custodiol-HTK provided good results as
long as the ischemic time did not exceed 4 hours. The 5
main features of the Custodiol-HTK solution claimed to
be useful for heart preservation are (1) its lower depolariz-
ing extracellular Kþ, low Naþ, low Ca2þ concentrations;
(2) the presence of energy substrate alpha-ketoglutarate;diovascular Surgery c Volume 142, Number 6 1559
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of mannitol to reduced cell swelling; and (5) a high histidine
(198 mmol/L) buffering to counter tissue acidosis during
cold global ischemia.20,34 In 2010, Lee and colleagues,35
using a rat transplant model, reported superiority of Custo-
diol-HTK over Celsior on the basis of lower serum creatine
kinase levels and less macroscopic deterioration of the graft
after 6 or 18 hours of cold storage. However, no pump func-
tion was reported, and, as the authors acknowledged, these
hearts were not loaded and cannot be extrapolated to clini-
cal conditions.35
The overall functional recoveries of hearts after cold
static storage in Custodiol-HTK solution reported in the lit-
erature vary widely. In 2000, Saitoh and colleagues36 re-
ported a return of 79.9% CO after 8 hours of cold static
storage (4C) compared with 4% in our study (which was
predominately coronary flow) (Figure 2, A–C). Saitoh and
colleagues’ study had the following differences: (1) male
Wistar rats versus male Sprague Dawley rats, (2) lower
working afterload (60 mm Hg) compared with 76 mm Hg
in our study, (3) unspecified Ca2þ level in their Custodiol-
HTK solution (Table 1 in Saitoh and colleagues), (3) 15
minutes of reperfusion in Langendorff mode at unspecified
temperatures compared with 5 minutes and 37C in our
study, and (4) working mode function for 25 minutes at un-
specified temperatures (Figure 1 in Saitoh and colleagues)
compared with 60 minutes and 37C in our study. Also in
their methods, Saitoh and colleagues state that hearts
were reperfused for 20 minutes in Langendorff and 40 min-
utes in working mode after cold storage.36 These omissions
and discrepancies in their methodology make functional
comparisons difficult. In 1992, Galinanes and colleagues37
reported a return of 22% CO in isolated rat hearts stored in
Custodiol-HTK for 8 hours (4C). In these latter experi-
ments, hearts were subjected to 15 minutes reperfusion fol-
lowed by 20 minutes working mode.37
In our study, the low COs in Custodiol-HTK (and Cel-
sior) hearts after 8 hours may have been due to the shorter
5-minute rewarming flush period (Figure 1). Warm reperfu-
sion in an oxygenated depolarized state may have promoted
unnatural heterogeneous membrane voltage, ionic and
metabolic imbalances, and possibly altered lipid membrane
organization, such as temperature-dependent phase transi-
tions influencing fluidity, which may have led to suboptimal
function after switching to working mode. Nonetheless, we
showed that normokalemic, polarizing AL preservation was
versatile at both profoundly hypothermic states and during
5-minute cold-to-warm transitions immediately after 8
hours of cold static storage. Functional deficits of Custo-
diol-HTK hearts may also have arisen from the lack of
broad-spectrum antioxidant protection. Schr€oder and col-
leagues14 recently reported cold-induced mediated oxidant
injury in isolated cells after Custodiol-HTK storage, and
they have proposed that the addition of iron chelators (or other1560 The Journal of Thoracic and Cardiovascular Surbroad-spectrum antioxidants) to the conventional Custodiol-
HTK solution may bolster protection. Custodiol-N base
solution (modified Custodiol-HTK solution) is now being
developed to address someof the concernswith the traditional
Custodiol-HTK solution.38
Possible Clinical Significance and Future Directions
The clinical significance of AL preservation solutions
exceeding the performance of 2 leading Food and Drug
Administration-approved heart preservation solutions Cus-
todiol-HTK and Celsior in isolated rat hearts after 8 hours
offers new opportunities. Despite decades of laboratory
studies with the reporting of some extraordinary functional
recoveries after 6, 8, 12, and 24 hours of heart preservation
in rat, rabbit, porcine, canine, and sheepmodels using amyr-
iad of preservation solutions, the clinical reality is that 4 to 5
hours remains the safe period for the human donor heart.
Storage time continues to be a critical factor determining
the viability of stored solid organs, and extending these
times may usher in a new era of organ donation. Longer
times may expand the use of organs from marginal beating
and non–beating heart donors, and donors may be sought
from larger geographic areas, including rural and remote re-
gions. Longer-term 15- to 24-hour preservation times are
currently being investigated with AL solutions, as well as
constant perfusion studies using isolated pig hearts and
kidneys. The possibility also exists that the new polarized
arrest and reperfusion paradigm may find utility in preserv-
ing other solid organs from a wide patient base, such as
lung, liver, and pancreas, or isolated cells, such as stem cells
or islet cells.
CONCLUSIONS
We report that AL polarized arrest solution with low
Ca2þ/high Mg2þ (0.22 mmol/L/2.6 mmol/L) returned 55%
CO, 101% heart rate, and 90% to 105% developed pres-
sures after 8 hours of cold static storage.When ALwas dou-
bled in concentration in the presence of melatonin (100
mmol/L) and insulin (0.01 IU/mL), the return of CO in-
creased to 78% with no detectable troponin T (<0.03 mg/
mL). In contrast, Custodiol-HTK hearts returned 4% CO,
16% heart rate, and 11% to 17% developed pressures,
and troponin T was 0.13 mg/mL in effluent 5 minutes after
the rewarm. Celsior hearts, despite an 86% return heart
rate, also failed to return sufficient left ventricular function
(10%) with a return of 25% CO and a troponin T level of
0.24 mg/mL.
The authors thank Professor Jakob Vinten-Johansen for com-
ments on the article.
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